ADHD Therapeutics Market

The ADHD therapeutics market was valued at approximately US$ 31.42 billion in 2024 and is projected to grow to US$ 66.27 billion by 2031, with an estimated CAGR of 10.8% from 2025 to 2031.

Market Insights and Analyst Perspective:Attention deficit/hyperactivity disorder (ADHD) is a multifaceted neurodevelopmental disorder that impacts an individual's capacity to concentrate, manage impulsive actions, and control hyperactivity. While it is primarily diagnosed in childhood, symptoms can extend into adolescence and adulthood. Treatment for ADHD typically employs a comprehensive strategy that includes behavioral therapy, educational support, and medications such as stimulants and non-stimulants.

The increasing prevalence of ADHD and the rising demand for therapeutic drugs are key factors driving market growth. However, the side effects linked to ADHD medications and their limited effectiveness pose challenges to the expansion of the ADHD therapeutics market.

Growth Factors and Challenges:According to a report from the Centers for Disease Control and Prevention (CDC) published in February 2022, around 6 million children aged 3 to 17 in the US were diagnosed with ADHD, representing 9.8% of the population from 2016 to 2019. Furthermore, a study published by PubMed Central in 2022 indicated that ADHD affects 5 to 7.2% of children and 2.5 to 6.7% of adults globally. Recent estimates suggest that the prevalence among adolescents in the US is significantly higher, at about 8.7% or 5.3 million. Although ADHD has been traditionally viewed as a childhood disorder, nearly 90% of children with ADHD continue to exhibit symptoms into adulthood. Additionally, 75% of adults with ADHD were not diagnosed during childhood, as per research findings. ADHD is often accompanied by comorbid conditions such as anxiety, depression, learning disabilities, and substance abuse, complicating treatment and necessitating a comprehensive approach that addresses both ADHD symptoms and these associated conditions. Medications like psychostimulants and non-stimulants are recommended to help children manage their ADHD symptoms in daily life and regulate behaviors that may disrupt various aspects of their lives, including personal relationships and academic performance. Consequently, these factors are driving the demand for ADHD medications, thereby enhancing the market share of ADHD therapeutics.

Nonetheless, the growth of the ADHD therapeutics market is hindered by the limited symptom relief and the side effects associated with these treatments. Common side effects of psychostimulant medications include reduced appetite, insomnia, heightened anxiety, increased irritability, stomach pain, and headaches. Additionally, when the medication's effects diminish, ADHD symptoms may re-emerge, leading to a "rebound" effect that can be more severe.

Strategic Insights

Report Segmentation and Scope:The "ADHD therapeutics market analysis" has been conducted by examining the following segments: drug type, age group, and distribution channel.

Segmental Analysis:The ADHD therapeutics market is categorized by drug type into stimulants and non-stimulant medications.

The stimulant drug segment accounted for a larger share of the ADHD therapeutics market in 2022 and is expected to exhibit a higher CAGR from 2022 to 2030.

ADHD Therapeutics Market by Drug Type - 2022 and 2030By age group, the ADHD therapeutics market is divided into pediatric & adolescent and adult segments. The pediatric & adolescent segment held a larger market share in 2022, while the adult segment is projected to experience a higher CAGR from 2022 to 2030.

Regarding distribution channels, the ADHD therapeutics market is segmented into hospital pharmacies, retail pharmacies, and E-commerce. In 2022, the hospital pharmacies segment captured the largest market share and is expected to achieve the highest CAGR during the period from 2022 to 2030.

Regional Analysis:The major regions analyzed for the ADHD therapeutics market report include North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

In 2022, North America held the largest share of the global market. Within North America, the US accounted for the largest market share in 2022 and is projected to maintain its leading position from 2022 to 2030. The growth of the ADHD therapeutics market is significantly driven by the high prevalence of ADHD in the US. According to Cingulate, approximately 6.4 million children and adolescents aged 4 to 17 were diagnosed with ADHD in 2022. Of this group, over 80% are receiving treatment, and about 65% continue to experience ADHD symptoms into adulthood. Additionally, factors such as improved patient affordability, favorable reimbursement policies, and heightened awareness of available medications are expected to further propel market growth.

Asia Pacific is the fastest-growing market for ADHD, attributed to the presence of key industry players and various strategic initiatives aimed at developing and marketing new products. For instance, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. announced positive outcomes from two six-week phase 3 clinical trials evaluating the effectiveness, safety, and tolerability of oral centanafadine, a new experimental drug intended for adult patients diagnosed with ADHD. The company also plans to investigate the effects of centanafadine in children with ADHD and discuss subsequent steps with the US Food and Drug Administration.

Industry Developments and Future Opportunities:The forecast for the ADHD therapeutics market can assist stakeholders in formulating their growth strategies. Key initiatives undertaken by major players in the market include:

In September 2023, Cingulate Inc. reported results from its Phase 3 study on the efficacy and safety of its lead candidate, CTx-1301 (dexmethylphenidate), for treating ADHD in adults. The company employs its patented Precision Timed Release (PTR) drug delivery platform technology to develop a pipeline of next-generation pharmaceutical products. The results were presented on September 8th at the 36th Annual Psych Congress in Nashville, TN.

In March 2022, Noven Pharmaceuticals, Inc., a wholly owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., received approval from the US Food and Drug Administration (FDA) for its XELSTRYM (dextroamphetamine) transdermal system, CII, for the treatment of ADHD in adults and pediatric patients aged six years and older.

In July 2021, Corium, Inc. launched AZSTARYS, an innovative medication that combines Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) in the US for the symptomatic treatment of patients aged 6 years and older. AZSTARYS received FDA approval in March 2021 and consists of a combination of two types of medication: 70% extended-release prodrug of d-MPH SDX (Schedule IV) and 30% immediate-release d-MPH (Schedule II).

In April 2021, Supernus Pharmaceuticals, Inc. announced that the US FDA had approved Qelbree (viloxazine extended-release capsules) for the treatment of ADHD in patients aged 6 to 17.

Competitive Landscape and Key Companies:Key players profiled in the ADHD therapeutics market report include Amneal Pharmaceuticals, Inc.; Novartis AG; Pfizer, Inc.; Eli Lilly and Company; Noven Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Services, Inc.; Corium Inc; Adlon Therapeutics LP; and Teva Pharmaceutical Industries Ltd. These companies implement product development strategies to meet the increasing demands of customers, enabling them to sustain their brand reputation.